Key Highlights

  • Third-quarter 2026 Revenue was $1.313 billion, up 29% from $1.016 billion in the same quarter of 2025.
  • Diluted EPS was $0.38, against a loss of $0.51 a year earlier and a market estimate of a loss of $1.10.
  • Net income was $162 million, compared with a net loss of $200 million in the third quarter of 2025.
  • The 2026 revenue growth outlook is now 15% to 25%, versus a prior outlook of up to 10%.
  • Year-end 2026 cash and investments are now projected at $8.1 billion to $8.3 billion.

Moderna (NASDAQ:MRNA), the Cambridge, Massachusetts-based mRNA medicine developer, reported third-quarter 2026 results before the market opened on Friday. Total revenue was $1.313 billion, compared with $1.016 billion a year earlier, an increase of 29%. Market estimates had pointed to revenue of $890.25 million.

The company attributed the increase mainly to higher international COVID Vaccine sales, supported by deliveries under long-term strategic government partnerships. Revenue was $780 million in the United States and $533 million in international markets.

Net income was $162 million, against a net loss of $200 million a year earlier. Diluted Earnings per Share were $0.38, compared with a loss of $0.51 per share in the third quarter of 2025. Cost of sales was $318 million, up 54% on higher product volume. Research and Development expenses were $583 million, down 27%, after certain late-stage infectious disease studies were completed and wound down.

Revenue Range and Year-End Cash Outlook Both Revised Higher for 2026

Moderna now projects 2026 total revenue growth of 15% to 25%, compared with a previous outlook of up to 10%. Research and development expenses are projected at about $2.7 billion, down from about $2.9 billion.

Year-end cash and investments are now projected at $8.1 billion to $8.3 billion, compared with a previous outlook of $4.7 billion to $5.2 billion. Cash and investments were $8.0 billion on Sept. 30, versus $6.9 billion on June 30. The company cited $2.6 billion in net proceeds from convertible notes and related capped call transactions, partly offset by a $950 million litigation settlement payment and cash used in operations. Most third-quarter product sales remained uncollected at quarter-end.

mFLUSIVA Approval, Intismeran Melanoma Data and the GSK Settlement

The FDA approved mFLUSIVA, Moderna's seasonal influenza vaccine, in August for adults aged 50 to 64, with Accelerated Approval for adults aged 65 and older. It is the company's fifth approved product globally, and the U.S. launch for the 2026-2027 season is limited because approval followed the annual contracting cycle. The flu/COVID combination vaccine remains under review in Japan, the United Kingdom and Australia.

Moderna and Merck (NYSE:MRK) presented Phase 3 results in October for intismeran autogene in resected high-risk melanoma. In the intention-to-treat population, intismeran combined with pembrolizumab reduced the risk of recurrence or death by 42% (HR=0.58) compared with pembrolizumab alone. An interim Phase 3 analysis of the norovirus vaccine candidate did not meet the statistical criteria for early success. On Oct. 28, Moderna and GSK agreed to settle all pending disputes, with Patent cross-licenses and no payments required.

Analyst Day on Nov. 12 and Pivotal Propionic Acidemia Data Are Next on the Calendar

Moderna has scheduled an Analyst Day for Nov. 12, 2026. The company said it anticipates additional intismeran readouts, pivotal data in propionic acidemia expected in 2026, and further regulatory approvals. Moderna is also awaiting FDA guidance on refiling its combination vaccine.